EGFR and lung cancer: Thus, EGFRTyr1068 was associated with lung cancer cells and tumors bearing EGFR-sensitizing mutations or with lung cancer cells and LCSCs that were sensitive to erlotinib treatment despite lack of EGFR mutation.